C difficile risk
Oral Bioavailability


Safety and efficacy of tigecycline in neonates has not been established, therefore dosages are not available.

Optional loading dose 1.5 mg/kg as a single dose, Max 100 mg/DOSE.
Maintenance dose: Children 8-11 years: 2.4 mg/kg/DAY IV divided q12h, MAX 100 mg/DAY,
Maintenance dose: Children 12 years or older: 2 mg/kg/DAY divided q12h, Max 100 mg/DAY.

Avoid use in children < 8 years due to adverse effects on tooth development.

Requires dose reduction in severe hepatic impairment; consult a pharmacist for dosage adjustment.

General Information

Reserved for highly resistant infections or when significant allergies restrict other options and when there is documented susceptibility

Associated with more treatment failures than alternatives and excess mortality - Black Box Warning

Nausea, vomiting.

Tetracycline related adverse events: photosensitivity, acute pancreatitis, increased BUN, acidosis, hypophosphatemia, rash (can be severe), abnormal hepatic enzymes and/or function tests.

Permanent tooth discoloration in children < 8 years old.

Recommended Infectious Disease consult.

Documented safety concerns (increaed mortality in adult studies).

Antimicrobial class: Tetracycline derivative

Average serum half life: No pediatric data.
Adults: Single dose: 27 hours; Multiple doses: 42 hours

Route of Elimination: 22% excreted in urine as unchanged drug; 59% in feces, primarily as unchanged drug

Clearance: Reduced by 25% in patient with moderate hepatic impairment and 55% in severe hepatic impairment